Uterine / Endometrial
To find out more about eligibility criteria, click on the ClinicalTrials.gov links and if you are interested in participating, email the coordinator by clicking on the envelope next to the coordinator's name and notify the coordinator.
Treatment stage |
Protocol Title |
ClinicalTrials.Gov Link |
Penn Research Coordinator |
Am I Eligible? |
|---|---|---|---|---|
| Recurrent | GOG 3104: Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01) | NCT06486441 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent | ATRN: A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors | NCT04905914 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent |
TPST-1495: Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors |
NCT04344795 | Jennifer Louie | Eligibility Criteria |
| Recurrent | NP-G2-044-P2-01: NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | NCT05023486 | Katie Hayes, RN | |
| Recurrent | NRG-GY031: A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer | NCT05950464 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent | A Phase 1/2 Study of CPI-0209 in Patients with Advanced Solid Tumors and Lymphomas | NCT04104776 | Katie Elkins | Eligibility Criteria |
| Recurrent | Phase 1/2 Study of REGN5668 (MUC16 X CD28, A Costimulatory Bispecific) Administered in Combination with Cemiplimab or REGN4018 (MUC16 X CD3) | NCT04590326 | Katie Hayes, RN | Eligibility Criteria |
| Recurrent | A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Gynecological Cancers | NCT05527184 | Kristina Powell | Eligibility Criteria |
| Recurrent | GOG 3119: A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer | NCT06952504 | Joseph Agyemang | Eligibility Criteria |
| Primary Radiation |
GynWPProton: Whole Pelvis Proton Radiation for Gynecologic Cancer |
NCT05758688 | Kelly Clark | Eligibility Criteria |